Chemical Property of Apremilast
Chemical Property:
- Boiling Point:741.342 °C at 760 mmHg
- PKA:14.01±0.20(Predicted)
- Flash Point:402.149 °C
- PSA：127.46000
- Density:1.382 g/cm3
- LogP:3.52590
- Storage Temp.:Refrigerator
- Solubility.:Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly, Heated)
- XLogP3:1.8
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:8
- Exact Mass:460.13042228
- Heavy Atom Count:32
- Complexity:825
- Purity/Quality:
-
99% *data from raw suppliers
Apremilast *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Dermatologic Agents, Psoriasis Agents
- Canonical SMILES:CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
- Isomeric SMILES:CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
- Recent ClinicalTrials:A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice
- Recent EU Clinical Trials:A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Beh?et’s Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis
- Recent NIPH Clinical Trials:A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
-
Description
Apremilast (Otezla) was approved by the FDA on March 21, 2014 for the treatment of adult patients with active psoriatic arthritis. Apremilast is a member of a new class of oral small molecule inhibitors of the phosphosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in immune cells, it results in elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which can regulate inflammatory mediators. The current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults. Apremilast is the first and only oral phosphodiesterase IV (PDE-
4) inhibitor and anti-tumor necrosis factor alpha (TNFa) agent
launched in the USA by Celgene for the treatment of active psoriatic
arthritis (PsA). Apremilast was also approved for the treatment
of moderate to severe plaque psoriasis in the USA. Later,
this drug was also approved in the European Union (EU) for both
indications. Although multiple approaches to the synthesis of
apremilast have been described, the most likely process scale approach involves the construction of the challenging stereogenic
benzylic carbon center by catalytic asymmetric hydrogenation.
-
Uses
Treating active psoriatic arthritis. It is also used to treat moderate to severe plaque psoriasis in certain patients. Apremilast is an oral phosphodiesterase 4 inhibitor used in the treatment of adults with active psoriatic arthritis and adults with moderate to severe plaque psoriasis.
-
Clinical Use
Treatment of active psoriatic arthritis (PsA) and
moderate to severe chronic plaque psoriasis (PSOR)
-
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: concentration reduced by rifampicin
- avoid.
Antidepressants: concentration possibly reduced by
St John’s wort - avoid.
Antiepileptics: concentration possibly reduced
by carbamazepine, fosphenytoin, phenobarbital,
phenytoin and primidone - avoid.
